US court invalidates two Skelaxin patents, increasing generic threat
This article was originally published in Scrip
Executive Summary
A US court has overturned two method-of-use patents protecting King Pharmaceuticals' best-selling muscle relaxant, Skelaxin (metaxalone), leading to new concerns about the threat of generic competition. There are currently no generic metaxalone products in the US, but several firms have filed ANDAs.